PCV13: Effective Against First-Episode CAP in Older Adults
April 20, 2015
The 13-valent pneumococcal conjugate vaccine reduced nearly by half vaccine-type community acquired pneumonia in adults aged 65 years and older.
Leah Lawrence
Intraperitoneal Chemotherapy Improves Ovarian Cancer Survival
March 24, 2015
The use of intraperitoneal chemotherapy for the treatment of advanced ovarian cancer resulted in a survival benefit over intravenous chemotherapy.
Early-Onset Alopecia May Signal Chemotherapy Response for Ovarian Cancer
March 18, 2015
Onset of alopecia within the first 3 cycles of chemotherapy was associated with improved survival in ovarian cancer patients who completed 6 cycles of chemo.
Possible Target Found in ARID1A-Mutated Ovarian Cancers
March 12, 2015
Researchers have discovered that ovarian cancers with ARID1A mutations may be sensitive to treatment with an inhibitor of EZH2 methyltransferase activity.
GLP-1 Receptor Agonists and Cardiovascular Outcomes: 3 Studies
February 20, 2015
Cardiovascular disease is the underlying cause of death in more than 60% of patients with T2DM. GLP-1 receptor agonists have shown promising cardioprotective effects.
Ovarian Cancer Disease Burden Affects Survival Despite R0 Resection
February 10, 2015
Despite achieving complete surgical resection, advanced epithelial ovarian cancer or primary peritoneal cancer patients with a high disease burden had worse survival outcomes than those with lower disease burden.
Early Natural Menopause Ups Risk of Heart Failure
February 2, 2015
Women who experience menopause before age 46 have an increased risk of heart disease, and smoking status can modifying this risk in older women.
Veliparib Trial Fails to Improve Outcomes in Ovarian Cancer
January 23, 2015
Adding the PARP inhibitor veliparib to cyclophosphamide did not improve response rates or progression-free survival in ovarian cancer.
The Utility of Vaginal Estrogens for Managing GSM
January 21, 2015
Vaginal estrogens are effective options for managing bothersome symptoms related to genitourinary syndrome of menopause in postmenopausal women.
Second-Line Ramucirumab Plus Chemotherapy Improved Survival in Metastatic Colorectal Cancer
January 13, 2015
The addition of ramucirumab to second-line FOLFIRI resulted in a delay in disease progression and improved survival in metastatic colorectal cancer patients.
